The University of Colorado Anschutz Gates Institute secured Investigational New Drug (IND) clearance from the FDA for a campus-developed CAR T-cell therapy. The program is described as the first U.S. CAR T therapy to receive clearance when developed entirely on a university campus. The milestone comes as CAR T manufacturing capacity and intellectual property models continue to evolve, with academic centers seeking pathways to move internally developed platforms into clinical testing. For the institute and broader CAR T ecosystem, FDA clearance marks a concrete step toward turning institution-built cell-engineering workflows into patient studies.